Literature DB >> 21874222

Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma.

Xuan Hong1, Zhao-Yang Yang, Meng Wang, Lu Lu, Ying-Hong Li, Xishan Hao, Gong-Yan Chen.   

Abstract

Although cancer cells initially respond to vinorelbine (NVB), the acquisition of resistance to the treatment is the main cause of chemotherapeutic failure in lung cancer. The intrinsic mechanism of drug resistance induced by NVB in lung cancer is not clear and tumor cell models to study NVB resistance have not been widely studied. We previously established a NVB resistant cell line, Anip973/NVB, derived from the Anip973 lung adenocarcinoma cell line. The aim of this study was to investigate the molecular mechanisms involved in the resistance to NVB in lung adenocarcinoma. Genetic profiles of Anip973/NVB and Anip973 cells were compared by microarray analysis and qRT-PCR. Tumor xenografts were obtained by grafting Anip973/NVB and Anip973 cells into nude mice and the xenograft response to NVB or control treatment was evaluated. Morphological assessment of xenograft tissues was performed by transmission electron microscopy (TEM). Immunohistochemistry (IHC) was used to compare Bcl-2 and MRP3 protein expression in xenografts. Fifty-five up-regulated genes and 88 down-regulated genes in Anip973/NVB cells compared with Anip973 cells were identified by cDNA microarray analysis. Up-regulation of MRP3 and Bcl-2 was confirmed by qRT-PCR. NVB inhibits xenografts of Anip973 growth but did not affect xenografts of Anip973/NVB growth. Ultrastructural changes observed by TEM showed that NVB induces apoptosis in the Anip973-treated group but not in the Anip973/NVB-treated group. Higher expression rates of Bcl-2 and MRP3 were observed in Anip973/NVB xenograft cells compared with Anip973 xenograft cells by IHC. In conclusion, in the present study, we identified a set of genes responsible for multidrug resistance in Anip973/NVB cells. Among them, MRP3 and Bcl-2 may participate in lung adenocarcinoma multidrug resistance induced by NVB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874222     DOI: 10.3892/ijmm.2011.779

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.

Authors:  Gabriela Carrasco-Torres; Samia Fattel-Fazenda; Guadalupe Soledad López-Alvarez; Rebeca García-Román; Saúl Villa-Treviño; Verónica Rocío Vásquez-Garzón
Journal:  Tumour Biol       Date:  2015-09-04

2.  Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy.

Authors:  Thomas Wibmer; Thierry Berghmans; Cornelia Kropf-Sanchen; Jean-Jacques Lafitte; Stefan Rüdiger; Marianne Paesmans; Ioanna Blanta; Arnaud Scherpereel; Kathrin M Stoiber; Wolfgang Rottbauer; Jean-Paul Sculier; Christian Schumann
Journal:  Lung       Date:  2013-04-07       Impact factor: 2.584

3.  ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.

Authors:  Yanbin Zhao; Hailing Lu; An Yan; Yanmei Yang; Qingwei Meng; Lichun Sun; Hui Pang; Chunhong Li; Xiaoqun Dong; Li Cai
Journal:  Sci Rep       Date:  2013-11-01       Impact factor: 4.379

4.  The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.

Authors:  Takao Nakanishi; Toshi Menju; Shigeto Nishikawa; Koji Takahashi; Ryo Miyata; Kei Shikuma; Terumasa Sowa; Naoto Imamura; Masatsugu Hamaji; Hideki Motoyama; Kyoko Hijiya; Akihiro Aoyama; Toshihiko Sato; Toyofumi F Chen-Yoshikawa; Makoto Sonobe; Hiroshi Date
Journal:  Cancer Med       Date:  2018-01-10       Impact factor: 4.452

5.  Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial.

Authors:  Ping Fang; Liqin Zhang; Xianru Zhang; Jiawen Yu; Jun Sun; Qi-An Jiang; Mingbao Zha; Anastasia P Nesterova; Hongbao Cao
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

6.  Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer.

Authors:  Xiangyang Zhang; Min Wang; Junyi Feng; Bin Qin; Chenglin Zhang; Chengshen Zhu; Wentao Liu; Yaohe Wang; Wei Liu; Lei Huang; Shuangshuang Lu; Zhimin Wang
Journal:  J Nanobiotechnology       Date:  2022-03-28       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.